Showing results (71-80 of 288) with videos related to

Sort By:
Pageof 29
The Journal of Urology|April 18, 2007
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancerSeth P Lerner, Catherine M Tangen, Heidi Sucharew, et al.
Urologic Oncology|February 19, 2004
The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancerMarileila Varella-Garcia, Bulent Akduman, Patrapim Sunpaweravong, et al.
World Journal of Urology|January 13, 2016
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care SystemS Scott Sutton, E David Crawford, Judd W Moul, et al.
The Journal of Urology|July 22, 2015
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available TherapiesE David Crawford, Celestia S Higano, Neal D Shore, et al.
The Journal of Urology|January 13, 2006
A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerE David Crawford, Oliver Sartor, Franklin Chu, et al.
Urology|April 19, 2005
Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening programAl Baha Barqawi, Brian K Golden, Colin O'Donnell, et al.
BJU International|October 6, 2018
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trialPaul F Pinsky, Eric Miller, Philip Prorok, et al.
The Journal of Urology|October 5, 2023
Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone AntagonistE David Crawford, Jason M Hafron, Frans Debruyne, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 11, 2013
Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancerHind T Hatoum, E David Crawford, Sandy Kildegaard Nielsen, et al.
BJU International|February 26, 2009
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-upLionel L Bañez, Gary W Blake, David G McLeod, et al.
Pageof 29